Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
Status:
Recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
Multicentric randomised trial. The goal of this clinical research study is to evaluate the
efficacy and safety of serplulimab combined with FOLFIRI+bevacizumab in the treatment of
pMMR/Ras/BRAF wild-type unresectable peritoneal metastasis of colon cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University